Darling Ingredients Inc. announced on October 21, 2024, the publication of preclinical and clinical studies in the Wiley Journal of Food Science and Nutrition. The studies focused on the impact of Nextida GC, a specific collagen peptide composition developed by Darling's Rousselot brand, on post-meal blood glucose spikes.
The research confirmed that participants in a clinical trial who consumed 5- or 10-gram doses of Nextida GC 30 minutes before a meal experienced an average reduction of 42% in their blood glucose spike after the meal. This finding supports the product's potential in mitigating post-meal glucose spikes in healthy individuals, including those with prediabetes.
This publication underscores the scientific robustness of Darling Ingredients' research and highlights Nextida GC as a significant breakthrough in collagen peptides. The company is committed to developing new collagen-based products that offer health benefits beyond traditional applications, addressing growing consumer demand for natural and effective health solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.